Russia will start giving the first approved drug to treat COVID-19 to patients next week

The Russian Drug and Financial Support Authority said the first approved drug in Russia to treat Covid-19 that Russia will begin next week to treat patients with the disease in a move that it hopes will reduce pressure on health care devices and accelerate the return to normal economic activity.
They said that Russian hospitals could begin giving the anti-viral drug, registered under the name Avifavir, to patients as of June 11.
They added that the drug manufacturer will produce enough of it to treat about 60,000 patients per month.
There is currently no vaccine for Covid-19 caused by the new coronavirus, and human trials of several antivirals have not yet shown effectiveness.
A new product from Gilead, called remdesivir, has had some positive results in small trials of people with COFED-19 and patients in some countries receive it in exceptional cases.
A Japanese company developed Avifavir in the late 1990s, and Fujifilm bought it when it expanded its business to include health care.
Russian scientists have made adjustments to the drug to increase its effectiveness, and Moscow will be ready to pass on the details of these adjustments to other parties within two weeks.
Japan is experimenting with the same drug, called Avigan. Prime Minister Shinzo Abe praised him, and the government has allocated -$- 128 million in funding, but it has not yet been approved for use.
On Saturday, the name Avivavir appeared on the list of drugs approved by the Russian government.
Clinical trials of the drug in which 330 people participated and revealed its success in treating the virus in most cases within four days.
The trials are due to be completed within a week, but the Ministry of Health approved the drug under special, rapid measures and a manufacturing process that started in March.
Clinical trials usually take several months to test the efficacy of drugs, and large numbers of patients are randomly selected.
Success in the first small-scale trials is not a guarantee of success in the extended experience.
For example, a study published this month linked the anti-malarial drug hydroxy chloroquine used by US President Donald Trump and promoted it, with an increase in the risk of death in Covid-19 patients in hospitals.
Russia managed to reduce the test time period because the Japanese drug on which Avivavir was developed was registered in 2014 and passed important test phases before it was modified by Russian experts.
The Russians think this drug will change the rules of the game. It will reduce stress on the health care system and reduce the number of those who develop them to critical situations. It is important to resume full economic activity in Russia.
Russia announced 423,741 cases of HIV infection, ranking third in the world on the list of the epidemic after Brazil and the United States. However, the official death toll is low, at 5,037, although this number is at issue until today 3 June.

Rate the article
Bad	1	2	3	4	5	6	7	8	9	10	Very good
Result : 100%							Participated in the vote : 1